Roles > EC 3.4.21.6 (coagulation factor Xa) inhibitor
Page last updated: 2024-08-05 15:47:32
EC 3.4.21.6 (coagulation factor Xa) inhibitor
An EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of coagulation factor Xa (EC 3.4.21.6).
ChEBI ID: 68581
Members (5)
| Member | Definition | Class |
|---|
| apixaban | A pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases. | apixaban |
| betrixaban | A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade. | betrixaban |
| edoxaban | A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. | edoxaban |
| pd 0348292 | A member of the class of pyrrolidines that is (2R,4R)-N(1)-(p-chlorophenyl)-4-methoxypyrrolidine-1,2-dicarboxamide in which the nitrogen of the 2-carbamoyl group has been substituted by a 2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl group. It is a synthetic organic anticoagulant compound that targets activated factor Xa in the coagulation cascade. | eribaxaban |
| rivaroxaban | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery. | rivaroxaban |
Research
Studies (6,148)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 147 (2.39) | 29.6817 |
| 2010's | 3,963 (64.46) | 24.3611 |
| 2020's | 2,038 (33.15) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|
| Trials | 1,023 (12.54%) | 5.53% |
| Reviews | 1,960 (24.02%) | 6.00% |
| Case Studies | 783 (9.60%) | 4.05% |
| Observational | 430 (5.27%) | 0.25% |
| Other | 3,964 (48.58%) | 84.16% |
Protein Targets (27)
Potency Measurements
Inhibition Measurements
Activation Measurements